Discover verified cancer discoveries

Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.

Filter discoveries

Results

Active filters:Clear all

2 verified discoveries match your filters.

Six-year OlympiA data sustain the adjuvant olaparib survival benefit in BRCA-mutated, HER2-negative early breast cancer

Evidence stage: High-Certainty EvidenceRegulatory status: FDA Approved
Cancer type
Breast Cancer
Published
August 13, 2026

In the randomized, double-blind, placebo-controlled OlympiA trial, one year of adjuvant olaparib significantly improved invasive disease-free survival (primary publication) and, in a later analysis, significantly improved overall survival as well…

Primary source cited

Last reviewed